CIBC Private Wealth Group
NRIX icon

CIBC Private Wealth Group’s Nurix Therapeutics NRIX Stock Holding History

CIBC Private Wealth Group’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$19 Hold
1
– – ﹤0.01% 3363
2025
Q3 		$9 Sell
1
-26
-96% -$270 ﹤0.01% 3071
2025
Q2 		$308 Buy
+27
New +$292 ﹤0.01% 2879

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CIBC Private Wealth Group's NRIX Position: Q4 2025 in Review

CIBC Private Wealth Group held its Nurix Therapeutics (NRIX) position steady in Q4 2025 at 1 share worth $19. The position accounts for ﹤0.01% of the portfolio, ranked #3363.

CIBC Private Wealth Group first reported a position in NRIX in Q2 2025 and has held it in 3 quarters since. The position peaked at $308 in Q2 2025. 182 funds tracked by Wall St. Rank hold NRIX as of Q4 2025.

  • CIBC Private Wealth Group held 1 share of Nurix Therapeutics worth $19 as of Q4 2025.
  • CIBC Private Wealth Group left its Nurix Therapeutics share count unchanged in Q4 2025.
  • Nurix Therapeutics made up ﹤0.01% of CIBC Private Wealth Group's portfolio in Q4 2025, its #3363 holding.
  • CIBC Private Wealth Group first reported a position in Nurix Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • CIBC Private Wealth Group's Nurix Therapeutics position peaked at $308 in Q2 2025.
  • 182 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.